Biotech Values

[jbog]

Over 100% oncology buyout premiums suggestive of Forty Seven deal, says Mizuho

07:10 FTSV, GILD Shares of Forty Seven (FTSV) traded up 30% after hours after Bloomberg indicated a potential takeover or partnership offer from Gilead Sciences (GILD) and other potential suitors, Mizuho analyst Mara Goldstein tells investors in a research note. Oncology-focused biotech acquisitions such as SynthorX at a 172% premium and ArQule at a 107% premium are suggestive of value for Forty Seven as a potential takeout candidate, says the analyst. She believes Forty Seven may have greater upside given magrolimab's novel innate-immune checkpoint mechanism and keeps a Buy rating on the shares with a $53 price target.

Read more at:
https://thefly.com/landingPageNews.php?id=3042059